ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from its clinical studies, selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, are now available on ASCO’s official website. Three of the six studies have been selected for rapid oral presentations, and three as poster presentation. These abstracts report data from ongoing studies evaluating the company’s three lead drug candidates, including BCR-ABL inhibitor olverembatinib(HQP1351); Bcl-2 inhibitor lisaftoclax (APG-2575);...

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) — Purecore Metals Inc. (CSE: PURE) (“Purecore” or the “Company”) is pleased to announce that it has engaged HEG & Associates Exploration Services Inc. (“HEG”) to plan and execute the Company’s 2026 exploration program at the Bankier Property, located in the Similkameen and Osoyoos Mining Divisions of southern British Columbia. About HEG HEG is a Kelowna-based geological services company specializing in exploration programs throughout the Okanagan region and similar geological settings. The company focuses on advancing early-stage projects through systematic, cost-effective field programs while maintaining operational flexibility and responsible exploration practices. With its head office located approximately 50 minutes from the Bankier Property, HEG is well positioned...

Hofseth BioCare ASA (“HBC”) has entered into an Exclusive License and Supply Agreement (the “Agreement”) with Fission Holdings LLC (“Fission”), a US-based affiliate and sales channel operator headquartered in Tulsa, Oklahoma. The Agreement grants Fission exclusive worldwide rights to import, market, distribute, and sell HBC’s ProGo® salmon-derived bioactive peptide ingredient within the Affiliate, Network Marketing, and Multi-Level Marketing (MLM) channel. To secure exclusivity, Fission shall purchase and pay for a minimum of $3m of ProGo® on or before 31 January 2027. The Parties have further agreed a projection of over $5m ProGo® on an annualised basis for HBC’s capacity allocation and inventory planning. The exclusivity period runs through 31 January 2027, after which the supply relationship continues between the Parties on a non-exclusive...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES MONTREAL, May 21, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland” or “Corporation”) (TSX-V: MD) is pleased to announce that it has completed a second and final tranche of its previously announced non-brokered private placement by issuing 6,926,123 units of Midland at a price of $0.45 per unit for aggregate gross proceeds of $3.1 million. Each unit consists of one common share and one warrant. Each warrant entitles the holder to purchase one common share of Midland at a price of $0.65 for a period of two years from the date of issuance. The total gross proceeds for this tranche and the one previously closed on May 11, 2026 is $5.3 million. Institutional investors have participated in the second tranche of the private placement,...

ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical data readouts anticipated beginning in Q1 2027 Waltham, Mass., May 21, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, in Chicago. Enrollment is ongoing in ASCEND (NCT07335497), a global, open-label Phase 1/2 clinical trial...

NEW YORK, NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) — Peace Acquisition Corp (the “Company”) announced today that it priced its initial public offering of 6,000,000 units at $10.00 per unit. The Company’s units will be listed on the Nasdaq Capital Market (“Nasdaq”) and will begin trading on May 22, 2026, under the ticker symbol “PECEU.” Each unit consists of one ordinary share, one right entitling its holder to receive one fifth of one ordinary share upon the Company’s completion of an initial business combination and one warrant entitling its holder to purchase one Ordinary Share for $11.50 per share, subject to adjustment. Once the securities comprising the units begin separate trading, the ordinary shares, rights and warrants are expected to be listed on Nasdaq under the symbols “PECE,” “PECER” and “PECEW,” respectively. The Company...

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026. Poster Presentation Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint InhibitorsPresenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer CenterSession: Developmental Therapeutics – ImmunotherapyDate: Saturday, May 30, 2026, 1:30 – 4:30...

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026 [²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026 Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were consistent with previously disclosed findings at AACR as of March 4, 2026 with continued deepening of responses; additional updates expected in late 2026 All three clinical programs continue to be well-tolerated based on safety findings reported...

LONDON, May 21, 2026 (GLOBE NEWSWIRE) — nVent (NYSE: NVT), a global leader in electrical connection and protection solutions, today announced its participation in William Blairs 46th Annual Growth Stock Conference on Wednesday, June 3, 2026. Beth Wozniak, Chair and Chief Executive Officer, will present at 8:00 a.m. CST. A webcast will be available on nVent’s Investor Relations website at https://investors.nvent.com/events-and-presentations. About nVentnVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems and ensure a more secure world. We design, manufacture, market, install and service high performance products and solutions that connect and protect some of the world’s most sensitive equipment, buildings and critical processes....